NCT02544724View on ClinicalTrials.gov

NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Lymphoma, Large B-Cell, Diffuse (DLBCL)
Interventions
BIOLOGICAL

NM-IL-12

Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle

Sponsors

Lead Sponsor

Neumedicines Inc.
All Listed Sponsors
lead

Neumedicines Inc.

INDUSTRY

NCT02544724 - NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy | Biotech Hunter | Biotech Hunter